BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 11177562)

  • 1. Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma.
    Wong RJ; Patel SG; Kim S; DeMatteo RP; Malhotra S; Bennett JJ; St-Louis M; Shah JP; Johnson PA; Fong Y
    Hum Gene Ther; 2001 Feb; 12(3):253-65. PubMed ID: 11177562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant treatment of hepatic malignancy: an oncolytic herpes simplex virus expressing IL-12 effectively treats the parent tumor and protects against recurrence-after resection.
    Jarnagin WR; Zager JS; Klimstra D; Delman KA; Malhotra S; Ebright M; Little S; DeRubertis B; Stanziale SF; Hezel M; Federoff H; Fong Y
    Cancer Gene Ther; 2003 Mar; 10(3):215-23. PubMed ID: 12637943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12.
    Wong RJ; Chan MK; Yu Z; Ghossein RA; Ngai I; Adusumilli PS; Stiles BM; Shah JP; Singh B; Fong Y
    Clin Cancer Res; 2004 Jul; 10(13):4509-16. PubMed ID: 15240543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma.
    Shin EJ; Wanna GB; Choi B; Aguila D; Ebert O; Genden EM; Woo SL
    Laryngoscope; 2007 Feb; 117(2):210-4. PubMed ID: 17204993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of an oncolytic virus secreting GM-CSF as combined oncolytic and immunotherapy for treatment of colorectal and hepatic adenocarcinomas.
    Malhotra S; Kim T; Zager J; Bennett J; Ebright M; D'Angelica M; Fong Y
    Surgery; 2007 Apr; 141(4):520-9. PubMed ID: 17383529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers.
    Varghese S; Rabkin SD; Liu R; Nielsen PG; Ipe T; Martuza RL
    Cancer Gene Ther; 2006 Mar; 13(3):253-65. PubMed ID: 16179929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin 12 secretion enhances antitumor efficacy of oncolytic herpes simplex viral therapy for colorectal cancer.
    Bennett JJ; Malhotra S; Wong RJ; Delman K; Zager J; St-Louis M; Johnson P; Fong Y
    Ann Surg; 2001 Jun; 233(6):819-26. PubMed ID: 11371740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective intravenous therapy of murine pulmonary metastases with an oncolytic herpes virus expressing interleukin 12.
    Wong RJ; Chan MK; Yu Z; Kim TH; Bhargava A; Stiles BM; Horsburgh BC; Shah JP; Ghossein RA; Singh B; Fong Y
    Clin Cancer Res; 2004 Jan; 10(1 Pt 1):251-259. PubMed ID: 14734477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokine-secreting herpes viral mutants effectively treat tumor in a murine metastatic colorectal liver model by oncolytic and T-cell-dependent mechanisms.
    Derubertis BG; Stiles BM; Bhargava A; Gusani NJ; Hezel M; D'Angelica M; Fong Y
    Cancer Gene Ther; 2007 Jun; 14(6):590-7. PubMed ID: 17431402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination gene therapy using multiple immunomodulatory genes transferred by a defective infectious single-cycle herpes virus in squamous cell cancer.
    Kim SH; Carew JF; Kooby DA; Shields J; Entwisle C; Patel S; Shah JP; Fong Y
    Cancer Gene Ther; 2000 Sep; 7(9):1279-85. PubMed ID: 11023201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcium depletion enhances nectin-1 expression and herpes oncolytic therapy of squamous cell carcinoma.
    Yu Z; Li S; Huang YY; Fong Y; Wong RJ
    Cancer Gene Ther; 2007 Aug; 14(8):738-47. PubMed ID: 17525764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic oncolytic herpes virus therapy of poorly immunogenic prostate cancer metastatic to lung.
    Varghese S; Rabkin SD; Nielsen PG; Wang W; Martuza RL
    Clin Cancer Res; 2006 May; 12(9):2919-27. PubMed ID: 16675589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical evaluation of "whole" cell vaccines for prophylaxis and therapy using a disabled infectious single cycle-herpes simplex virus vector to transduce cytokine genes.
    Ali SA; McLean CS; Boursnell ME; Martin G; Holmes CL; Reeder S; Entwisle C; Blakeley DM; Shields JG; Todryk S; Vile R; Robins RA; Rees RC
    Cancer Res; 2000 Mar; 60(6):1663-70. PubMed ID: 10749137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination vascular delivery of herpes simplex oncolytic viruses and amplicon mediated cytokine gene transfer is effective therapy for experimental liver cancer.
    Zager JS; Delman KA; Malhotra S; Ebright MI; Bennett JJ; Kates T; Halterman M; Federoff H; Fong Y
    Mol Med; 2001 Aug; 7(8):561-8. PubMed ID: 11591892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivity of squamous cell carcinoma lymph node metastases to herpes oncolytic therapy.
    Yu Z; Li S; Huang YY; Lin SF; Fong Y; Wong RJ
    Clin Cancer Res; 2008 Mar; 14(6):1897-904. PubMed ID: 18347193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor.
    Toda M; Martuza RL; Rabkin SD
    Mol Ther; 2000 Oct; 2(4):324-9. PubMed ID: 11020347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncolytic herpesvirus effectively treats murine squamous cell carcinoma and spreads by natural lymphatics to treat sites of lymphatic metastases.
    Wong RJ; Joe JK; Kim SH; Shah JP; Horsburgh B; Fong Y
    Hum Gene Ther; 2002 Jul; 13(10):1213-23. PubMed ID: 12133274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
    Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
    Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic viral therapy with a combination of HF10, a herpes simplex virus type 1 variant and granulocyte-macrophage colony-stimulating factor for murine ovarian cancer.
    Goshima F; Esaki S; Luo C; Kamakura M; Kimura H; Nishiyama Y
    Int J Cancer; 2014 Jun; 134(12):2865-77. PubMed ID: 24265099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.